Hyperhidrosis Treatment Market Size, Growth and Trends Analysis By Type (Primary Hyperhidrosis, Secondary Generalized Hyperhidrosis), By Treatment (Botulinum Toxin Injections, Topical Treatment, Surgical Treatment, Oral Medication, Microwave Therapy, Others) and By End-User (Dermatology Clinics, Ambulatory Surgery Centers, Payers/Patients, Others)-Forecast to 2030

Hyperhidrosis Treatment Market Synopsis

The Hyperhidrosis Treatment Market is anticipated to reach USD 1365.39 Million by 2030 at 5.90% CAGR during the forecast period 2022-2030.Despite being one of the most commonly occurring conditions, the hyperhidrosis treatment market continues to grow at a moderate rate. Antiperspirants and topical products are the first line of treatment in the hyperhidrosis treatment market. However, there is no permanent cure to hyperhidrosis yet. However, there has been high activity in terms of technological developments and product developments in the past few years. Also, with growing awareness about the treatment options and patient’s inclination towards novel approaches has been an encouraging factor for the companies to invest in this market.

Hyperhidrosis Treatment Market Influencer

The increasing usage of botulinum toxin for the treatment of hyperhidrosis has been instrumental in boosting the market growth. The rising number of products by key players in the market are likely to act as a promising factor for the growth of the hyperhidrosis treatment market.

Market Drivers

• Increasing research studies being conducted for the treatment of hyperhidrosis


• Extensive use of botulinum toxin injections


• Development in laser and electronic therapy for hyperhidrosis treatment


• Rising support by the public and private companies


• Increasing efforts to increase awareness about hyperhidrosis. For instance, in November 2018, the International Hyperhidrosis Society ran an awareness campaign, “Hyperhidrosis Awareness Month.” Through this campaign, they reached more than 170,000 healthcare professionals, and about 101,000 visitors looked up their campaign website from 206 different countries.


• Increasing prevalence of hyperhidrosis. In the US, the prevalence of hyperhidrosis has grown from 2.8% in 2004 to 4.8% in 2018. Nearly 58% of these people reported having primary hyperhidrosis. In Germany, the prevalence of hyperhidrosis is almost 16.3%. The prevalence of primary and secondary hyperhidrosis is 13.9% in Japan.

Market Restraints

• Lack of approved products in the hyperhidrosis treatment market and unavailability of a permanent cure


• The high cost of treatment

Hyperhidrosis Treatment Market Segmentation

By Type

• Primary Hyperhidrosis: It is a disorder with symptoms such as abnormal sweating. The sweating is not necessarily related to exercise or heat. The most commonly affected areas by hyperhidrosis are armpits, palms of the hands, soles of the feet, under the breasts, and groin area. The primary hyperhidrosis segment captures the larger hyperhidrosis treatment market share.

• Secondary Generalized Hyperhidrosis: In secondary generalized hyperhidrosis the sweating is caused due to another medical condition such as hypertension and cardiovascular diseases, among others. It does not affect any particular body part, and the and perspiration occurs all over the affected person’s body.

By Treatment

• Botulinum Toxin Injections: Botulinum toxin (Botox) is a neurotoxin, which is a relatively new treatment approach for the treatment of hyperhidrosis. Botox is the Food and Drug Administration (FDA)-approved treatment for axillary hyperhidrosis. Generally, doctors recommend Botox injections only when the patient continues to experience the hyperhidrosis episodes despite the use of prescription antiperspirants, and the condition does not improve.

• Topical Treatment: Topical treatment generally includes over-the-counter (OTC) antiperspirants. These are considered the first line of treatment for hyperhidrosis. If the patient is not relieved by using the OTC antiperspirants, prescription antiperspirants are used.

• Surgical Treatment: The surgical treatment includes sweat gland removal surgery and endoscopic thoracic sympathectomy (ETS). Sweat gland removal surgery is done when there is a need for permanent sweat gland removal in case of severe armpit sweating. ETS is a minimally invasive surgical procedure commonly used for the hyperhidrosis of hands. Besides that, lasers treatments are also a common surgical procedure.

• Oral Medication: Although there are no specific drugs targeted for the treatment of hyperhidrosis, oral medicines such as anticholinergics have found some success and are commonly used. Some of the examples of anticholinergics are glycopyrrolate, oxybutynin, benztropine, propantheline, and others.

• Microwave Therapy: Also known as microwave thermolysis, works on the principle of directing energy to the sweat glands of the armpit and destroying them.

• Others: The other segment includes iontophoresis.

By End-User

• Dermatology Clinics: Dermatology clinics account for the largest hyperhidrosis treatment market share of this segment in the hyperhidrosis treatment market. Dermatology clinics offer a number of treatments ranging from Botox treatment to surgical and laser therapy.

• Ambulatory Surgery Centers: Ambulatory surgical centers offer outpatient services related to hyperhidrosis treatment. Ambulatory surgery centers are the fastest-growing segment in the hyperhidrosis market.

• Payers/Patients: This segment includes the individual patients who tend to buy the medication, topical creams, and antiperspirants for the treatment of hyperhidrosis.

• Others: This segment includes research organizations and academic institutions.

By Region

• 
  Americas: The largest regional hyperhidrosis treatment market. Countries such as the US and Canada have been at the forefront of the healthcare industry over the years. High awareness about hyperhidrosis, adoption of novel therapeutic approaches, and high per capita disposable incomes are contributing factors for the growth of the market in this region.

• 
  Europe: Europe is the second-largest hyperhidrosis treatment market for hyperhidrosis treatment. The increasing number of players involved in the development of the new therapeutic approaches, rising government support for the research & development, and rising awareness about the disorder are some of the factors driving the growth in the region.

• 
  Asia-Pacific: The Asia-Pacific region is anticipated to be the fastest-growing region in the hyperhidrosis treatment market. This region has been witnessing a surge in the number of people afflicted with the disorder. Additionally, growing awareness of this disorder has been an important factor in the growth of the hyperhidrosis market.

• 
  Middle East & Africa: The smallest market due to limited healthcare infrastructure, lack of awareness about the disease condition, and low per capita disposable incomes in underdeveloped regions of the Middle East and Africa.

Hyperhidrosis Treatment Market Key Players

• Allergan PLC (Ireland)


• Brickell Biotech Inc. (US)


• Cynosure (US)


• Dermadry Laboratories lnc. (Canada)


• Dermira Inc. (US)


• GlaxoSmithKline PLC (UK)


• Miramar Labs, Inc. (US)


• Sesderma (Spain)


• Ulthera Inc. (US)